Next Article in Journal
Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart Failure
Previous Article in Journal
Aerobic Threshold Identification in a Cardiac Disease Population Based on Correlation Properties of Heart Rate Variability
Review

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis

1
Department of Clinical Medicinal Sciences, Konyang University, Nonsan 32992, Korea
2
Department of Internal Medicine, Division of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03063, Korea
3
Evidence-Based and Clinical Research Laboratory, Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Paula M. Macedo and Gianluca Aimaretti
J. Clin. Med. 2021, 10(18), 4078; https://doi.org/10.3390/jcm10184078
Received: 7 July 2021 / Revised: 25 August 2021 / Accepted: 7 September 2021 / Published: 9 September 2021
(This article belongs to the Section Endocrinology & Metabolism)
To investigate the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists on glycemic variability (GV), the mean amplitude of glucose excursion (MAGE), mean blood glucose (MBG) levels, and percentage of time maintaining euglycemia were evaluated. Randomized controlled trials evaluating the efficacy of SGLT-2 inhibitors and GLP-1 agonists for treating people with diabetes were selected through searches of PubMed, EMBASE, and other databases. Sixteen studies were finally analyzed. There were no differences in the reductions in MAGE after treatment with SGLT-2 inhibitors or GLP-1 agonists (standardized mean difference (SMD) = −0.59, 95% CI = −0.82 to −0.36 vs. SMD = −0.43, 95% CI = −0.51 to −0.35, respectively), and treatment with SGLT-2 inhibitors was associated with an increased reduction in MBG levels (SMD = −0.56, 95% CI = −0.65 to −0.48, p < 0.00001). Monotherapy and add-on therapy with medications were correlated with MAGE and MBG level reductions. In conclusion, SGLT-2 inhibitors and GLP-1 agonists were associated with a reduction in GV and could be alternatives for treating people with diabetes. View Full-Text
Keywords: diabetes mellitus; GLP 1 agonist; glycemic variability; SGLT2 inhibitor diabetes mellitus; GLP 1 agonist; glycemic variability; SGLT2 inhibitor
Show Figures

Figure 1

MDPI and ACS Style

Lee, H.; Park, S.-e.; Kim, E.-Y. Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. J. Clin. Med. 2021, 10, 4078. https://doi.org/10.3390/jcm10184078

AMA Style

Lee H, Park S-e, Kim E-Y. Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2021; 10(18):4078. https://doi.org/10.3390/jcm10184078

Chicago/Turabian Style

Lee, Heeyoung, Se-eun Park, and Eun-Young Kim. 2021. "Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis" Journal of Clinical Medicine 10, no. 18: 4078. https://doi.org/10.3390/jcm10184078

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop